HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA ‘Actively Investigating’ Asbestos In Cosmetics; Claire’s Rebuts New Allegations

This article was originally published in The Rose Sheet

Executive Summary

Health Canada’s investigation cleared Claire’s makeup previously linked to asbestos by Scientific Analytical Institute, the same lab whose asbestos findings Tween Brands disputed last year before launching a recall based on its own testing. Cosmetics manufacturers using talc should try to keep up.

You may also be interested in...



FDA To Hold Public Meeting In February on Cosmetic Talc-Asbestos Test Methods

Recommendations from an FDA-led interagency work group regarding methods for detecting and measuring asbestos in talc and talc-containing cosmetics will be presented at the agency’s planned public meeting in Silver Spring, MD, on 4 February. The recommendations are summarized in the FDA's meeting notice, which follows contentious cosmetic product recalls based on asbestos findings.

J&J Doing Damage Control Following Reuters Report On Asbestos ‘Lurking’ In Johnson’s Powder

J&J shares are down nearly 12% since Reuters reported Dec. 14 that the firm has known for decades about toxic asbestos in its Johnson’s Baby Powder talc. The news outlet’s probe turned up nothing that hasn’t been raised by plaintiff attorneys, but throws the central issues of contention into high relief for its global audience.

FDA Shopping For 3D Tissue Bioprinter, Cosmetic Contamination Testing Services

Recent procurement activities show an agency increasingly focused on cosmetics’ safety vis-a-vis microbial threats and, in the case of talc-containing products, asbestos. Meanwhile, FDA seeks a 3D bioprinter to use in organ toxicity studies as an alternative to traditional animal models.

Related Content

Topics

UsernamePublicRestriction

Register

RS121516

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel